NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

>>This is to most powerfully immunise people against their tumours, Pollard explains. Because today’s standard-of-care chemotherapy can damage the immune system, giving the viral immunotherapy first, means the immune activity and memory are activated before the system is compromised.

https://news.cancerresearchuk.org/2026/01/06/the-switch-and-the-trojan-horse-how-viral-vectors-and-synthetic-enhancers-could-change-glioblastoma-treatment/

Another major advantage to this timeline is that roughly three weeks after a trial participant is given Trogenix’s immunotherapy, they will have their tumour removed. Interrogating the tissue that the neurosurgeon excises will give an immediate indication of whether the AAV is working. The team will be able to check for cell loss, for expression of HSV-TK and IL-12, and for other robust indicators that the immune system is responding as planned.